Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
InMed Pharmaceuticals ( (INM) ) has issued an update.
InMed Pharmaceuticals has published a study revealing the potential of cannabinol (CBN) as an anti-inflammatory agent for skin diseases. The research highlights how CBN modulates the endocannabinoid system, showing promise for treating conditions like psoriasis and atopic dermatitis. This development could pave the way for therapeutic and cosmetic applications, underscoring CBN’s role in regulating skin inflammation and offering protective benefits.
Learn more about INM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue